The Microbiome New Drug Companies Council under the Korea Bio Association announced on the 28th that it will hold a seminar titled "Microbiome Technology in the Era of Great Transformation" at the Korea Bio Park auditorium.
This seminar is planned with the purpose of sharing future regulatory issues related to microbiome pharmaceuticals and new development directions. About 120 major domestic microbiome industry representatives and researchers are expected to attend.
The main presentations include ▲ Regulatory considerations for microbiome drug development (Jinwook Kang, Health Research Officer, Cell and Gene Therapy Division, Ministry of Food and Drug Safety) ▲ The role of the gut-brain axis in the onset of Alzheimer's disease (Inhee Mook, Professor, Seoul National University College of Medicine) ▲ Data-driven approaches to understanding the human microbiome (Nomina, Professor, Hanyang University College of Engineering) ▲ Interactions between the skin microbiome and the host (Jihwan Yoo, Professor, Yonsei University College of Medicine) ▲ The role of gut microbiota in multiple sclerosis (Hongseop Yoon, Professor, Handong University College of Life Sciences).
The Bio Association explained that through this seminar, "It will be an opportunity to confirm the regulatory authorities' guidelines and directions for the approval of microbiome-based pharmaceuticals, while also exploring the potential for information-based approaches in future microbiome pharmaceutical R&D fields such as Alzheimer's, multiple sclerosis, and skin." They added, "We hope this will be an opportunity to seek new knowledge and business creation by sharing the research experience and know-how of government and academic experts in the microbiome field."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
